Aclarion is a healthcare technology company. The first application of Co.'s technology is focused on improving surgical decision making when surgical intervention is being contemplated for patients with low back pain. Co.'s commercial product, NOCISCAN-LS, utilizes its proprietary biomarkers and algorithms to provide surgeons with information about which intervertebral discs are determined to be consistent with generating pain, and which are not. The main technology underlying NOCISCAN-LS is the use of Magnetic Resonance spectroscopy to identify the chemical makeup of intervertebral discs with a focus on identifying specific proprietary biomarkers. The ACON average annual return since 2022 is shown above.
The Average Annual Return on the ACON average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACON average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACON average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|